INTRODUCTION: High frequency repetitive transcranial magnetic stimulation (HF-rTMS) of the left dorsolateral prefrontal cortex (DLPFC) might be a promising strategy to treat depression, but not all patients show a positive outcome. OBJECTIVE: In this open study, we evaluate whether a favorable HF-rTMS treatment outcome could be predicted by baseline prefrontal brain glucose metabolism (CMRglc), measured by 18fluorodeoxyglucose positron emission tomography (18FDG-PET). METHODS: A sample of 21 antidepressant-free, treatment-resistant depression (TRD) patients of the melancholic subtype received 10 sessions of HF-rTMS delivered on the left DLPFC. Patients underwent a static 18FDG-PET before and after HF-rTMS treatment. RESULTS: Forty-three percent of the patients showed a reduction of at least 50% on their Hamilton Rating Scale for Depression scores. Higher baseline metabolic activities in the DLPFC and the anterior cingulate cortex (ACC) were associated with better clinical outcome. Successful HF-rTMS treatment was related to metabolic changes in subdivisions of the ACC (Brodmann areas 24 and 32). CONCLUSION: This biological impact of HF-rTMS on regional brain CMRglc explains to some extent how HF-rTMS may improve moods in TRD patients. Larger sham-controlled HF-rTMS treatment studies are needed to confirm these results.
INTRODUCTION: High frequency repetitive transcranial magnetic stimulation (HF-rTMS) of the left dorsolateral prefrontal cortex (DLPFC) might be a promising strategy to treat depression, but not all patients show a positive outcome. OBJECTIVE: In this open study, we evaluate whether a favorable HF-rTMS treatment outcome could be predicted by baseline prefrontal brain glucose metabolism (CMRglc), measured by 18fluorodeoxyglucose positron emission tomography (18FDG-PET). METHODS: A sample of 21 antidepressant-free, treatment-resistant depression (TRD) patients of the melancholic subtype received 10 sessions of HF-rTMS delivered on the left DLPFC. Patients underwent a static 18FDG-PET before and after HF-rTMS treatment. RESULTS: Forty-three percent of the patients showed a reduction of at least 50% on their Hamilton Rating Scale for Depression scores. Higher baseline metabolic activities in the DLPFC and the anterior cingulate cortex (ACC) were associated with better clinical outcome. Successful HF-rTMS treatment was related to metabolic changes in subdivisions of the ACC (Brodmann areas 24 and 32). CONCLUSION: This biological impact of HF-rTMS on regional brain CMRglc explains to some extent how HF-rTMS may improve moods in TRD patients. Larger sham-controlled HF-rTMS treatment studies are needed to confirm these results.
Authors: Deborah C.W. Klooster; Iris N. Vos; Karen Caeyenberghs; Alexander Leemans; Szabolcs David; René M.H. Besseling; Albert P. Aldenkamp; Chris Baeken Journal: J Psychiatry Neurosci Date: 2020-07-01 Impact factor: 6.186
Authors: Thiago M Fidalgo; J Leon Morales-Quezada; Guilherme S C Muzy; Noelle M Chiavetta; Mariana E Mendonca; Marcus V B Santana; Oscar F Goncalves; Andre R Brunoni; Felipe Fregni Journal: J ECT Date: 2014-03 Impact factor: 3.635
Authors: Turhan Canli; Lei Yu; Xiaoqing Yu; Hongyu Zhao; Debra Fleischman; Robert S Wilson; Philip L De Jager; David A Bennett Journal: Transl Psychiatry Date: 2018-01-10 Impact factor: 6.222
Authors: Peter M Kreuzer; Astrid Lehner; Winfried Schlee; Veronika Vielsmeier; Martin Schecklmann; Timm B Poeppl; Michael Landgrebe; Rainer Rupprecht; Berthold Langguth Journal: Sci Rep Date: 2015-12-15 Impact factor: 4.379
Authors: Helge H O Müller; Sebastian Moeller; Caroline Lücke; Alexandra P Lam; Niclas Braun; Alexandra Philipsen Journal: Front Neurosci Date: 2018-04-10 Impact factor: 4.677